Viridian Therapeutics, Inc. VRDN Derivative Gain Loss On Derivative Net
Derivative Gain Loss On Derivative Net at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeGainLossOnDerivativeNet.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s derivative gain loss on derivative net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s derivative gain loss on derivative net?
- Viridian Therapeutics, Inc. (VRDN) reported derivative gain loss on derivative net of $7.53M in Q1 2026.
- What does derivative gain loss on derivative net mean?
- This reflects the net non-cash impact of changes in the fair value of derivative financial instruments held by the company. Because these gains or losses do not represent actual cash inflows or outflows, they are added back to or subtracted from net income to determine operating cash flow. It indicates the volatility and risk exposure related to the company's derivative hedging or financing activities.